ABT-100

• UNSPSC Description:

  ABT-100 is a potent, highly selective and orally active farnesyltransferase inhibitor. ABT-100 inhibits cell proliferation (IC50s of 2.2 nM, 3.8 nM, 5.9 nM, 6.9 nM, 9.2 nM, 70 nM and 818 nM for EJ-1, DLD-1, MDA-MB-231, HCT-116, MiaPaCa-2, PC-3, and DU-145 cells, respectively), increases apoptosis and decreases angiogenesis. ABT-100 possesses broad-spectrum antitumor activity[1].

• Target Antigen:

  Apoptosis; Farnesyl Transferase

• Type:

  Reference compound

• Related Pathways:

  Apoptosis;Metabolic Enzyme/Protease

• Applications:

  Cancer-programmed cell death

• Field of Research:

  Cancer

• Assay Protocol:

  https://www.medchemexpress.com/abt-100.html

• Purity:

  98.18

• Solubility:

  DMSO : 50 mg/mL (ultrasonic)

• Smiles:

  N#CC1=CC(C2=CC=C(OC(F)(F)F)C=C2)=C(OC[C@](O)(C3=CC=C(C#N)C=C3)C4=CN=CN4C)C=C1

• Molecular Weight:

  504.46

• References & Citations:

  [1]Ferguson D, et al. Antitumor activity of orally bioavailable farnesyltransferase inhibitor, ABT-100, is mediated by antiproliferative, proapoptotic, and antiangiogenic effects in xenograft models. Clin Cancer Res. 2005 Apr 15;11(8):3045-54.

• Shipping Conditions:

  Blue Ice

• Storage Conditions:

  -20°C (Powder, protect from light)

• Clinical Information:

  No Development Reported

• CAS Number:

  450839-40-4